China's Integration of HPV Vaccine into National Immunization Program: Current Challenges and Future Path

Area of Science:

• Public Health
• Epidemiology
• Vaccinology

Background:

• Cervical cancer, primarily caused by persistent human papillomavirus (HPV) infection, represents a significant global health challenge.
• Prophylactic HPV vaccines, introduced in 2006, have been pivotal in primary prevention strategies.
• China's national HPV immunization strategy is advancing, with vaccination soon to be integrated into the National Immunization Program.

Purpose of the Study:

• To analyze the current status and challenges of HPV vaccination in China.
• To identify key barriers hindering vaccine uptake among the target population.
• To propose strategies for improving HPV immunization coverage and advancing cervical cancer elimination goals.

Main Methods:

• Review of national HPV immunization strategy progress and vaccine coverage data.
• Identification and analysis of barriers to vaccine uptake, including public concerns, misinformation, and logistical issues.
• Examination of ongoing debates regarding optimal dosing schedules and population expansion for vaccination.

Main Results:

• Despite policy advancements, HPV vaccine coverage among girls aged 9-14 years in China remains critically low (estimated 4% first-dose uptake in 2022).
• Significant barriers include vaccine preferences, safety concerns, social media misinformation, inadequate healthcare provider knowledge, and lack of school-based vaccination programs.
• Discussions persist on single-dose regimens and extending vaccination to older females and males.

Conclusions:

• Substantial efforts are required to overcome low HPV vaccine coverage in China.
• Strengthening health education, combating vaccine hesitancy, and optimizing vaccination delivery strategies are essential.
• These interventions are critical for achieving the goal of cervical cancer elimination in China.